Akero Therapeutics, Inc.
AKRODelisted Dec 9, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001744659
Akero Therapeutics, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 9, 2025; 265 institutions reported holding it in 13F filings for Q3 2025, worth $4.34B in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 265
- Q3 2025, +10 vs. previous quarter
- 13F value
- $4.34B
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Superinvestors holding AKRO, Q3 2025
No superinvestor reported holding AKRO at the end of Q3 2025.
Latest insider trades
Open-market purchases and sales by Akero Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 14, 2025 (view filing) | Oct 10 | 4 days | Cheng AndrewPresident and CEO | SSale | −30.0K | $53.98 | −$1.62M | −5.4%526.1K after | 10b5-1 |
| Oct 9, 2025 (view filing) | Oct 7 | 2 days | Rolph TimothyChief Scientific Officer | SSale | −12.5K | $46.08 | −$576.0K | −7.0%166.6K after | 2 lots10b5-1 |
| Oct 3, 2025 (view filing) | Oct 1 | 2 days | Young JonathanChief Operating Officer | SSale | −12.5K | $47.75 | −$596.9K | −6.0%196.9K after | 2 lots10b5-1 |
| Sep 12, 2025 (view filing) | Sep 11 | 1 day | Young JonathanChief Operating Officer | SSale | −586 | $43.02 | −$25.2K | −0.3%196.9K after | |
| Sep 12, 2025 (view filing) | Sep 11 | 1 day | Yale CatrionaChief Development Officer | SSale | −659 | $43.02 | −$28.4K | −0.7%90.8K after | |
| Sep 12, 2025 (view filing) | Sep 11 | 1 day | White William RichardChief Financial Officer | SSale | −659 | $43.02 | −$28.4K | −1.1%57.8K after | |
| Sep 12, 2025 (view filing) | Sep 11 | 1 day | Rolph TimothyChief Scientific Officer | SSale | −553 | $43.02 | −$23.8K | −0.3%166.6K after | |
| Sep 12, 2025 (view filing) | Sep 10-11 | 2 days | Cheng AndrewPresident and CEO | SSale | −31.8K | $43.23 | −$1.37M | −6.3%473.9K after | 4 lots10b5-1 |
| Sep 10, 2025 (view filing) | Sep 8 | 2 days | Rolph TimothyChief Scientific Officer | SSale | −12.5K | $44.17 | −$552.1K | −7.0%167.1K after | 2 lots10b5-1 |
| Sep 4, 2025 (view filing) | Sep 2 | 2 days | Young JonathanChief Operating Officer | SSale | −12.5K | $46.09 | −$576.1K | −6.0%197.5K after | 3 lots10b5-1 |
Top 10 13F holders, Q3 2025
The largest institutional positions in Akero Therapeutics, Inc. at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Janus Henderson Group PLC | 6,280,305 | $298.2M | 0.14% | −458,251−6.8% | Reduced |
| General Atlantic LLC | 5,733,989 | $272.2M | 8.17% | 00.0% | Unchanged |
| BlackRock, Inc. | 5,702,634 | $270.8M | 0.00% | −76,778−1.3% | Reduced |
| RTW Investments, LP | 5,477,561 | $260.1M | 3.20% | 00.0% | Unchanged |
| Vanguard Group Inc | 4,526,920 | $214.9M | 0.00% | −2,708−0.1% | Reduced |
| Wellington Management Group LLP | 4,251,861 | $201.9M | 0.04% | +841,915+24.7% | Added |
| Deep Track Capital, LP | 4,000,978 | $190.0M | 5.30% | +958,380+31.5% | Added |
| Avoro Capital Advisors LLC | 3,955,555 | $187.8M | 2.43% | +455,555+13.0% | Added |
| Price T Rowe Associates Inc | 3,809,859 | $180.9M | 0.02% | −699,466−15.5% | Reduced |
| State Street Corp | 3,414,306 | $162.1M | 0.01% | +668,742+24.4% | Added |